RNXT vs. FDMT, ENGN, PBYI, LFVN, KRRO, SLS, FTLF, NKTX, CYBN, and TNGX
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include 4D Molecular Therapeutics (FDMT), enGene (ENGN), Puma Biotechnology (PBYI), LifeVantage (LFVN), Korro Bio (KRRO), SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.
RenovoRx vs.
4D Molecular Therapeutics (NASDAQ:FDMT) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
RenovoRx has higher revenue and earnings than 4D Molecular Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
4D Molecular Therapeutics received 46 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 65.56% of users gave 4D Molecular Therapeutics an outperform vote while only 56.52% of users gave RenovoRx an outperform vote.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 9.1% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
4D Molecular Therapeutics currently has a consensus price target of $29.56, suggesting a potential upside of 746.86%. RenovoRx has a consensus price target of $7.00, suggesting a potential upside of 488.24%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than RenovoRx.
4D Molecular Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
In the previous week, RenovoRx had 3 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 8 mentions for RenovoRx and 5 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.78 beat RenovoRx's score of -0.19 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
4D Molecular Therapeutics' return on equity of -28.00% beat RenovoRx's return on equity.
Summary
4D Molecular Therapeutics beats RenovoRx on 12 of the 17 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
This page (NASDAQ:RNXT) was last updated on 5/24/2025 by MarketBeat.com Staff
Buy RNXT Stock Free RNXT Stock Alerts